1. A pharmaceutical composition suitable for oral administration which comprises: (a) S1P receptor agonist and (b) mannitol, wherein the composition is a solid dosage form, mannitol has a large specific surface area, a S1P receptor agonist selected from 2-amino-2- [2- (4-octylphenyl) ethyl] propane-1,3- 10 diol (FTY720), its pharmaceutically acceptable salts and FTY20-fosfata.2. A composition according to claim 1, wherein the S1P receptor agonist is 2-amino-2- [2- (4-octylphenyl) ethyl] propane-1,3-diol or a pharmaceutically acceptable soli.3. A composition according to claim 1, wherein the S1P receptor agonist is 2-amino-2- [2- (4-octylphenyl) ethyl] propane-1,3-diola.4. A composition according to any one of the preceding claims, wherein the mannitol is prepared from spray-dried kompozitsii.5. A composition according to claim 1 or 2, wherein the mannitol has a mean particle size of from 100 microns to 300 or 150 to 250 mkm.6. A composition according to claim 1 or 2, wherein the mannitol has a bulk density of 0.4 to 0.6 g / ml or from 0.45 to 0.55 g / ml.7. A composition according to claim 1 or 2, wherein the mannitol has a surface area of one particle of from 1 to 7 m / D.8. A composition according to claim 1 or 2, wherein the composition further comprises mannitol, inositol, xylitol or lactitol, for example, further includes ksilit.9. A composition according to claim 1 or 2, wherein the S1P receptor agonist is micronized and / or is pre proseyannym.10. A composition according to claim 1 or 2, further comprising zamaslivatel.11. A composition according to claim 10, comprising from 0.01 to 20 wt.% S1P.12 receptor agonist. A composition according to claim 1 or 2, comprising from 90 to 99.5 wt.% Mannita.13. A composition according to claim 1 or 2, wherein the composition is in unit dosage form and1. Фармацевтическая композиция, пригодная для перорального введения, которая содержит:(а) агонист рецептора S1P и(б) маннит,причем эта композиция представляет собой твердую
